{
    "clinical_study": {
        "@rank": "25233", 
        "acronym": "AZD3293hADME", 
        "arm_group": {
            "arm_group_label": "AZD3293", 
            "arm_group_type": "Experimental", 
            "description": "7 subjects will receive AZD3293"
        }, 
        "brief_summary": {
            "textblock": "This study will be an open-label, non-randomized, absorption, metabolism, and excretion\n      study to evaluate the mass balance, metabolite profiles, and rates and routes of elimination\n      of [14C]-AZD3293 and derived metabolites following administration as a single 100-mg\n      (containing approximately 150 \u00b5Ci) oral dose (as an oral solution)"
        }, 
        "brief_title": "A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Mass Balance Study"
        ], 
        "detailed_description": {
            "textblock": "This study will be an open-label, non-randomized,absorption, metabolism, and excretion\n      study to evaluate the mass balance, metabolite profiles, and rates and routes of elimination\n      of [14C]-AZD3293 and derived metabolites following administration as a single 100-mg\n      (containing approximately 150 \u00b5Ci) oral dose (as an oral solution) following at least an\n      8-hour fast from food (not including water).  Seven healthy male subjects will be enrolled\n      in the study at a single study site to complete a minimum of 6 subjects.  The study will\n      consist of 2 visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:  Healthy male subjects between 18 and 55 years of age, inclusive, at\n        the time of consent with suitable veins for cannulation or repeated venipuncture; 2) Body\n        weight between 50 to 100 kg, inclusive; 3) Within BMI range 19 to 30 kg/m2, inclusive; 4)\n        In good health, as determined by no clinically significant findings from medical history,\n        physical examination with neurological examination, 12-lead ECG, and vital signs as judged\n        by the Investigator;\n\n        -\n\n        Exclusion Criteria:\n\n        Participation in any prior study of AZD3293 or previous enrollment in the present study;\n        2) Significant history or clinical manifestation of any metabolic, allergic,\n        dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,\n        neurological, or psychiatric disease or disorder which, in the opinion of the\n        Investigator, may either put the subject at risk because of participation in the study,\n        interfere with absorption, distribution, metabolism or excretion of drugs, or influence\n        the results or the subject's ability to participate in the study; 3)  History of\n        significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other\n        substance, unless approved by the Investigator;\n\n        -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126514", 
            "org_study_id": "D5010C00007", 
            "secondary_id": "AZD3293 hADME"
        }, 
        "intervention": {
            "arm_group_label": "AZD3293", 
            "description": "7 subjects will receive AZD3293", 
            "intervention_name": "AZD3293", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Beta secretase inhibitor", 
            "Alzheimer disease"
        ], 
        "lastchanged_date": "May 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Covance", 
            "last_name": "Irene Mirkin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximum observed concentration (Cmax) parameters will be calculated, for AZD3293, its metabolite; and [14C]-AZD3293-derived total radioactivity.", 
            "measure": "PK parameters measured by assessment of AUC over time and Maximum observed concentration (Cmax)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 25"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety assessments including vital sign measurements, ECGs, physical examinations, clinical laboratory evaluations, and a record of adverse events (AEs), will be performed before and following investigational product administration.", 
                "measure": "Safety assessments including vital sign measurements, ECGs, physical examinations, clinical laboratory evaluations, and a record of adverse events (AEs).", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 25"
            }, 
            {
                "description": "The Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to assess the psychiatric health of subjects.", 
                "measure": "The Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Time to maximum observed concentration (tmax) will be calculated for AZD3293 and its metabolite; and [14C]-AZD3293-derived total radioactivity.", 
                "measure": "Time to maximum observed concentration (tmax)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Area under the concentration-time curve from Hour 0 to the last measurable concentration (AUC0-t), will be calculated for AZD3293 and its metabolite ; and [14C]-AZD3293-derived total radioactivity concentrations.", 
                "measure": "Area under the concentration-time curve", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Area under the concentration-time curve extrapolated to infinity (AUC0-\u221e), apparent terminal elimination rate constant (\u03bbZ), will be calculated for AZD3293 and its metabolite ; and [14C]-AZD3293-derived total radioactivity.", 
                "measure": "Area under the concentration-time curve extrapolated to infinity (AUC0-\u221e)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Apparent terminal elimination half-life (t1/2), will be calculated for AZD3293 and its metabolite; and [14C]-AZD3293-derived total radioactivity.", 
                "measure": "Apparent terminal elimination half-life (t1/2)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Apparent oral clearance (CL/F) (AZD3293 only), will be calculated for AZD3293 concentrations.", 
                "measure": "Apparent oral clearance (CL/F)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Apparent volume of distribution (Vz/F) (AZD3293 only) will be calculated for AZD3293 concentrations.", 
                "measure": "Apparent volume of distribution (Vz/F)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }, 
            {
                "description": "Ratios for AUC0- including the ratio of total radioactivity in whole blood/plasma; and the ratio of AZD3293 in plasma and total radioactivity in plasma, will be calculated.", 
                "measure": "Ratios for AUC0-", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 25"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}